Aprepitant

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Retrieved on: 
Tuesday, March 12, 2024
Webcast, Bupivacaine, Granisetron, Aprepitant, Meloxicam, Heron

ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.

Key Points: 
  • ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.
  • APONVIE® Net Product Sales: Net Product Sales of APONVIE for the three and twelve months ended December 31, 2023 were $0.5 million and $1.4 million, respectively, with no sales in the comparable prior year periods.
  • CINVANTI® Net Product Sales: Net Product Sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2023 were $24.3 million and $94.9 million, respectively, which increased from $23.1 million and $87.3 million, respectively, for the same periods in 2022.
  • SUSTOL® Net Product Sales: Net Product Sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2023 were $3.8 million and $13.0 million, respectively, which increased from $3.0 million and $10.2 million, respectively, for the same periods in 2022.

Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Retrieved on: 
Tuesday, November 14, 2023
Sale, Fresenius (company), EBITDA, Webcast, New product development, SAN, Markman, Therapy, Bupivacaine, Investment, Depreciation, Patient, VAN, Meloxicam, New Drug Application, Aprepitant, Growth, PDUFA, Heron, Patent, Optimism, Pharmaceutical industry, Risk management, Beauty salon, Cryptocurrency

I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.

Key Points: 
  • I am delighted to offer this quarterly update on our expectations for the fourth quarter and to unveil our 2024 guidance.
  • Guidance for 2023 and 2024:
    The Company is updating guidance for the remainder of 2023 and establishing guidance for the full year 2024 that reflects the growth potential of the product portfolio and the output of our continual operational improvements.
  • Full-year 2023 net product sales guidance for the oncology care franchise is being increased to a range of $104 million to $106 million from a prior range of $99 million to $103 million.
  • EBITDA (excluding stock compensation) expected in the range of ($10 million) to ($6 million) in the fourth quarter of 2023.

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
Prescription Drug User Fee Act, Centers for Medicare & Medicaid Services, Marketing, New Drug Application, Meloxicam, Center for Medicare and Medicaid Innovation, Vomiting, Medicare, Net, Aprepitant, Shanda, Comparables, Bupivacaine, Patient, PONV, Investment, SAN, Heron, PDUFA, Webcast, Growth, Research, Therapy, Video game, Management, Pharmaceutical industry, Internet service provider, Cryptocurrency

SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.

Key Points: 
  • SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.
  • First quarter 2023 net product sales grew 26% to $29.6 million, compared to the first quarter of 2022.
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three months ended March 31, 2023 was $3.5 million.
  • Net product sales of APONVIE for the three months ended March 31, 2023 were $0.3 million.

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, March 23, 2023
Centers for Medicare & Medicaid Services, Pharming, New Drug Application, Meloxicam, Center for Medicare and Medicaid Innovation, Pain, Vomiting, Medicare, Net, Aprepitant, Shanda, Bupivacaine, Hospital, Patient, PONV, Investment, SAN, Heron, PDUFA, Webcast, Nausea, Growth, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Video game, Pharmaceutical industry, Cryptocurrency

SAN DIEGO, March 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and twelve months ended December 31, 2022 and highlighted recent corporate updates.

Key Points: 
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2022 were $3.9 million and $10.2 million, respectively.
  • Net product sales of ZYNRELEF for the three and twelve months ended December 31, 2021 were $0.8 million and $2.9 million, respectively (ZYNRELEF was launched July 1, 2021).
  • We currently expect first quarter 2023 ZYNRELEF demand unit sales to increase approximately 10% over the prior quarter.
  • Since launch on July 1, 2021 through December 31, 2022, 793 unique accounts purchased ZYNRELEF with 90% of those accounts reordering the product.

Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults

Retrieved on: 
Monday, March 6, 2023
MD, Woman, IV, Physician, Milk, SAN, Pharming, Headache, Brain, Aprepitant, Pregnancy, Hormone, Pain, Vomiting, Therapy, Patient, Heron, Plasma, Cochrane, Food, Food and Drug Administration, PONV, Allergy, FDA, Warfarin, Constipation, Tell, Intrauterine device, Dizziness, Vitamin, Fatigue, Condom, Sales, Pharmaceutical industry, Birth control

SAN DIEGO, March 6, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous (IV) use in adults for the prevention of PONV.

Key Points: 
  • Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron.
  • "This launch supports our ongoing commitment to delivering innovative solutions that improve the postoperative experience by addressing the two most common concerns after surgery, postoperative pain with ZYNRELEF® and postoperative nausea and vomiting with APONVIE."
  • The launch of APONVIE will now allow providers to prevent PONV without the limitations of the current oral route of administration.
  • Report side effects to Heron at 1-844-437-6611 or to the Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov/medwatch .

Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises

Retrieved on: 
Monday, January 9, 2023
Food, Therapy, Aprepitant, Regulation of tobacco by the U.S. Food and Drug Administration, Vomiting, SAN, Elective surgery, Shanda, PONV, Patient, Growth, FDA, Heron, Pharming, CMS, New Drug Application, CINV, Beauty salon, Pharmaceutical industry, Video game

SAN DIEGO, Jan. 9, 2023 /PRNewswire/ --Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today highlights progress in its acute care and oncology care franchises.

Key Points: 
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for ZYNRELEF were approximately $10.1 million.
  • Fourth-Quarter 2022 Net Product Sales: Preliminary fourth-quarter 2022 net product sales for the oncology care franchise were approximately $25.3 million.
  • Full-Year 2022 Net Product Sales: Preliminary full-year 2022 net product sales for the oncology care franchise were approximately $96.6 million versus guidance of $93 million to $95 million.
  • Full-Year 2023 Net Product Sales Guidance: Heron expects full-year 2023 net product sales for the oncology care franchise of $99 million to $103 million.

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates

Retrieved on: 
Tuesday, November 8, 2022
Food, RA, NDA, New Drug Application, Safety, Analgesic, Pharming, Growth, HEC, Webcast, Nausea, Achievement, News, FDA, Patient, Investor relations, Company, Granisetron, Compliance, Private Securities Litigation Reform Act, SAN, MEC, AC, Ankle, Health Canada, PONV, Cancer, Cyclophosphamide, Forward-looking statement, Drug discovery, COVID-19, Antiemetic, Regulation of tobacco by the U.S. Food and Drug Administration, Aprepitant, Net, Human, Pain, 3D ultrasound, Surgical incision, Elective surgery, Boxed warning, Vomiting, Investment, Foot, Head, Hospital, Nasdaq, Heron, U.S. Securities and Exchange Commission, Bupivacaine, Meloxicam, Therapy, Pharmaceutical industry, Platinum, Beauty salon, Aquaculture, Video game

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three and nine months ended September 30, 2022 and highlighted recent corporate updates.

Key Points: 
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and nine months ended September 30, 2022 were $2.7 million and $6.3 million, respectively.
  • Net product sales of ZYNRELEF for both the three and nine months ended September 30, 2021 were $2.1 million (ZYNRELEF was launched July 1, 2021).
  • The APONVIE (aprepitant) injectable emulsion NDA was approved by the U.S. Food and Drug Administration (FDA) on September 16, 2022.
  • 2022 Oncology Care Franchise Net Product Sales Guidance: Heron currently expects full-year 2022 net product sales for the oncology care franchise of $93 million to $95 million.

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Prevention of Postoperative Nausea and Vomiting (PONV) in Adults

Retrieved on: 
Wednesday, September 28, 2022
Brand Institute, AMA, Safety, Food and Drug Administration, FDA, Food, Vomiting, World, Name, World Health Organization, Review, Approximation error, Therapy, Patient, Health Canada, Pharmacology, PONV, European Medicines Agency, WHO, American Medical Association, HC, Aprepitant, EMA, C.E.O, Pharmaceutical industry

APONVIE (aprepitant) is a substance P/neurokinin-1 receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.

Key Points: 
  • APONVIE (aprepitant) is a substance P/neurokinin-1 receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • APONVIE is the first and only intravenous formulation of aprepitant for PONV prevention.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Heron Therapeutics on the FDA approval of APONVIE," said Brand Institute's Chairman and C.E.O., James L. Dettore.
  • The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

Retrieved on: 
Friday, September 16, 2022
Headache, Dizziness, Condom, Bachelor of Medicine, Bachelor of Surgery, Cochrane, Milk, FRCA, IV, Master of Science, COVID-19, Pain, Heron, Risk, Brain, FDA, Food, Ondansetron, Hormone, Vomiting, U.S. Securities and Exchange Commission, Division, Company, Intrauterine device, News, Private Securities Litigation Reform Act, Achievement, Pharming, Therapy, Forward-looking statement, Patient satisfaction, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Pregnancy, Physician, Duke University Hospital, Standard of care, Antiemetic, Investor relations, Media, Media contacts database, NASDAQ, PONV, Allergy, Clinician Administered PTSD Scale, SAN, Vitamin, Constipation, Aprepitant, Warfarin, Webcast, CINV, Drug discovery, MHSC, Plasma, Fatigue, Pharmaceutical industry, Birth control, Woman, Anesthesia

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Key Points: 
  • Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to ondansetron.
  • "With the approval of APONVIE our acute care portfolio now addresses the two most common concerns of patients and clinicians after surgery, postoperative pain and postoperative nausea and vomiting.
  • APONVIE (aprepitant) injectable emulsion is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • APONVIE is the same formulation as Heron's approved CINVANTI (aprepitant) injectable emulsion formulation for prevention of chemotherapy-induced nausea and vomiting (CINV).

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

Retrieved on: 
Thursday, June 30, 2022
PONV, Cyclophosphamide, FDA, Bupivacaine, Media, Media contacts database, Patient, Head, Research, Pharming, Therapy, COVID-19, Heron, AC, Workforce, Foot, Aprepitant, Cancer, Ankle, Company, U.S. Securities and Exchange Commission, Surgical incision, Coronavirus, Vomiting, Compliance, Forward-looking statement, Pain, Health Canada, MEC, SG, Food, Investment, Human, Drug discovery, Private Securities Litigation Reform Act, Nasdaq, Investor relations, Quart, Safety, Boxed warning, Analgesic, Granisetron, Board, PDUFA, HEC, RA, Antiemetic, Regulation of tobacco by the U.S. Food and Drug Administration, Nausea, NDA, News, Director, Bank, Pharmaceutical industry

SAN DIEGO, June 30, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced a corporate restructuring and cost reduction plan to address the current market dynamics and prepare the company for long-term sustainability. The Company expects these actions will result in annualized cost savings of $43 million and will enable Heron to maintain a streamlined organization to support its acute care and oncology care franchises and extend its cash runway.

Key Points: 
  • "To address the current market realities and the macro headwinds facing many commercial-stage biotechnology companies, we are enacting critical plans to protect Heron's long-term sustainability and growth plans.
  • The Company's restructuring and cost reduction plan includes the following:
    Workforce reduction: The majority of the cost savings will result from a significant workforce reduction across the Company's research and development organization, with approximately 70% of the total employee reductions coming from research and development.
  • Dr. Quart continued, "These restructuring and cost reduction actions, while difficult, are necessary to address the challenging operating landscape and better position Heron to improve the lives of patients while creating long-term value for shareholders.
  • On behalf of the Board of Directors, I would like to recognize our valued colleagues who are departing Heron.